A 28-day, randomised, double blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 7.5 mg per day in patients with chronic obstructive pulmonary disease.
Laufzeit: 01.01.2005 - 31.12.2007